Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BM330
- Development stage
- Preclinical
- Lead developer
- Biomissile Pharmaceuticals
- Modality
- Cell Therapies
01
Overview
BM330 is a novel preclinical-stage drug developed by Biomissile. It is classified as an NKT cell therapy and functions as a natural killer T cell modulator, indicating its role in influencing the activity of natural killer T cells within the immune system. The drug is currently being investigated for its potential in cancer treatment.
Beyond the preview
Go deeper on BM330.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BM330.